Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2015103 | 1.00 | AHCY (0.38) | AHCYADCY5 | |
| SCHEMBL2024502 | 0.91 | ADCY5 (0.37) | AHCYADCY5 | |
| SCHEMBL2024506 | 0.91 | ADCY5 (0.37) | AHCYADCY5 | |
| SCHEMBL13457899 | 0.82 | AHCY (0.39) | AHCYADCY5 | |
| SCHEMBL2021176 | 0.78 | AHCY (0.46) | AHCYADCY5 | |
| SCHEMBL30827039 | 0.70 | LMNA (0.52) | ADCY5 | |
| SCHEMBL30827036 | 0.70 | ADCY5 (0.45) | ADCY5 | |
| SCHEMBL9564683 | 0.67 | KDM4E (0.45) | ADCY5 | |
| SCHEMBL3670718 | 0.67 | ADCY5 (0.35) | ADCY5 | |
| SCHEMBL3768830 | 0.67 | ADCY5 (0.35) | ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
| WO-2010027935-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | AHCY, AHCYL1, BHMT | AHCY 1/4885ADCY5 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.